✨ Free AI Report
Medios AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Medios AG
Company Research

Medios AG: Business Overview, Financials & Competitive Analysis

Medios AG scores 6/10 on the AskCyborg Cyborg Score (Solid). Medios is a niche specialty pharma distributor with stable cash generation but limited growth catalysts in mature markets. Medios operates in a stable specialty pharma niche with recurring revenue from pharmaceutical distribution and manufacturing. However, the company faces competitive pressures in consolidated markets, indicated by elevated P/E ratios and modest.

What is Medios AG's industry? Medios AG (medios.ag) operates in Pharmaceutical Distribution & Specialty Pharma Manufacturing. AskCyborg classifies Medios AG under Pharmaceutical Distribution & Specialty Pharma Manufacturing in its company registry.

Medios AG is a German specialty pharmaceutical distributor and manufacturer supplying specialty drugs primarily to German pharmacies and healthcare providers. The company operates through patient-specific therapies ma...

6/ 10Solid

Cyborg Score thesis

Medios is a niche specialty pharma distributor with stable cash generation but limited growth catalysts in mature...

Read the full analyst-debate transcript →
Industry Pharmaceutical Distribution & Specialty Pharma Manufacturing
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Medios AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Medios AG

AskCyborg analysts argue the bull and bear cases for Medios AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Medios AG OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Medios AG Overview

Pro stress-test →

Medios AG is a German specialty pharmaceutical distributor and manufacturer supplying specialty drugs primarily to German pharmacies and healthcare providers. The company operates through patient-specific therapies manufacturing, international business activities, and pharmaceutical supply segments focused on oncology, neurology, and other chronic disease treatments.

Strategic Profile

Pro stress-test →

Medios positions itself as a competence partner in specialty pharma supply chain management, combining pharmaceutical distribution with patient-centric manufacturing capabilities like custom infusions and cytostatic preparations. The company leverages its established market position in Germany while expanding international operations to serve European pharmacies and healthcare institutions.

Competitive Landscape

Pro stress-test →

Medios competes in specialty pharma distribution against larger global players like Cardinal Health and AmerisourceBergen, as well as regional European distributors. The company's advantage lies in specialized manufacturing capabilities for patient-specific therapies and focus on high-value specialty drugs for chronic diseases, but it faces consolidation pressures typical of pharmaceutical distribution.

Industry Context

Medios AG operates in Pharmaceutical Distribution & Specialty Pharma Manufacturing.

Key facts

Founded: 1980 · Headquarters: Berlin, Germany · Employees: 1,000 · Revenue: €2.5B · Market cap: €401M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Medios AG.

  • Operates three distinct business segments: Patient-Specific Therapies, Pharmaceutical Supply, and International Business, providing revenue diversification
  • Specializes in high-value specialty pharmaceuticals for chronic/rare diseases (oncology, autoimmunity, neurology, ophthalmology, hemophilia) with higher margins than generic pharma
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Executive leadership changes with CEO Matthias Gärtner and COO Mi-Young Miehler departing under mutual agreement
  • RecentSecured syndicated financing from leading financial institutions for growth initiatives
  • +1 moreTrack every material event for Medios AG as it happens. Explore monitoring →
Get alerted when Medios AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Specialty Pharmaceutical DistributionGlobal pharmaceutical and medical products distributor→Specialty Pharmaceutical DistributionLarge-scale pharmaceutical distributor and services provider→Regional Specialty PharmaEuropean pharmaceutical wholesale distributor→

Compare Medios AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Medios AG operates in Pharmaceutical Distribution & Specialty Pharma Manufacturing. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Distribution & Specialty Pharma Manufacturing research →
NEW · MCP server

Ask your AI assistant about Medios AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Medios AG and its top competitor on Cyborg Score”
“What did Medios AG do this quarter?”
“Is Medios AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Medios AG do?+
Medios AG is a German specialty pharmaceutical distributor and manufacturer supplying specialty drugs primarily to German pharmacies and healthcare providers. The company operates through patient-specific therapies ma...
What is Medios AG's Cyborg Score?+
Medios AG has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Medios AG's main competitors?+
Named competitors include Specialty Pharmaceutical Distribution, Specialty Pharmaceutical Distribution, Regional Specialty Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full Medios AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Medios AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Medios AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.